Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Part D Plan Sponsors Should Keep It Simple, Blue Cross Exec Says

This article was originally published in The Pink Sheet Daily

Executive Summary

Sponsors should refrain from offering too many plans in light of the short enrollment period, Independence Blue Cross Senior VP Daniel Lyons suggests at CMS' Advisory Panel on Medicare Education meeting. Independence Blue Cross will offer a basic benefit as well as actuarial equivalent and enhanced alternatives.

You may also be interested in...



CMS Is Evaluating Options For Extending Medicare Rx Enrollment Deadline

The Centers for Medicare & Medicaid Services is evaluating Part D implementation options that would extend the May 15, 2006 Medicare drug benefit enrollment deadline, CMS Administrator Mark McClellan said March 22

CMS Is Evaluating Options For Extending Medicare Rx Enrollment Deadline

The Centers for Medicare & Medicaid Services is evaluating Part D implementation options that would extend the May 15, 2006 Medicare drug benefit enrollment deadline, CMS Administrator Mark McClellan said March 22

Medicare Rx Plan Candidates Down To The Wire: Applications Due March 23

CMS will accept applications from Part D prescription drug plans, Medicare Advantage drug benefit providers and cost contractors. Related reporting requirements are scheduled to be posted on CMS’ website in April.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS061819

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel